Beam Therapeutics Inc
BEAM
查看详细走势图
34.600USD
+7.050+25.59%
交易中 （美东）报价延迟15分钟
3.51B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+25.59%
5天
+27.49%
1月
+25.77%
6月
+63.52%
今年开始到现在
+24.82%
1年
+31.11%
查看详细走势图
TradingKey Beam Therapeutics Inc股票评分
单位: USD 更新时间: 2026-01-09操作建议
Beam Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业中等水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名74/396位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价45.47。中期看，股价处于平稳状态。近一个月，市场表现一般，但技术面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Beam Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Beam Therapeutics Inc亮点
亮点风险
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
业绩增长期
公司处于发展阶段，最新年度总收入63.52M美元
利润高增长
公司净利润处于行业前列，最新年度总收入63.52M美元
估值合理
公司最新PE估值-6.24，处于3年历史合理位
机构减仓
最新机构持股103.69M股，环比减少10.68%
HACAX持仓
明星投资者HACAX持仓，最新持仓市值3.42K
分析师目标
根据
17
位分析师
买入
评级
45.467
目标均价
+69.40%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Beam Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Beam Therapeutics Inc简介
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
公司代码BEAM
公司Beam Therapeutics Inc
CEOEvans (John M)
网址https://beamtx.com/
常见问题
Beam Therapeutics Inc(BEAM)的当前股价是多少？
Beam Therapeutics Inc(BEAM)的当前股价是 34.600。
Beam Therapeutics Inc的股票代码是什么？
Beam Therapeutics Inc的股票代码是BEAM。
Beam Therapeutics Inc股票的52周最高点是多少？
Beam Therapeutics Inc股票的52周最高点是35.250。
Beam Therapeutics Inc股票的52周最低点是多少？
Beam Therapeutics Inc股票的52周最低点是13.525。
Beam Therapeutics Inc的市值是多少？
Beam Therapeutics Inc的市值是3.51B。
Beam Therapeutics Inc的净利润是多少？
Beam Therapeutics Inc的净利润为-376.74M。
现在Beam Therapeutics Inc(BEAM)的股票是买入、持有还是卖出？
根据分析师评级，Beam Therapeutics Inc(BEAM)的总体评级为买入，目标价格为45.467。
Beam Therapeutics Inc(BEAM)股票的每股收益（EPS TTM）是多少
Beam Therapeutics Inc(BEAM)股票的每股收益（EPS TTM）是-4.414。
相关品种
